X4 Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell XFOR and other ETFs, options, and stocks.

About XFOR

X4 Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. It is focused on mavorixafor which is being marketed in the U.S. under the trade name xolremdi. 

CEO
Adam R. Craig
CEOAdam R. Craig
Employees
45
Employees45
Headquarters
Boston, Massachusetts
HeadquartersBoston, Massachusetts
Founded
2010
Founded2010
Employees
45
Employees45

XFOR Key Statistics

Market cap
347.51M
Market cap347.51M
Price-Earnings ratio
-3.38
Price-Earnings ratio-3.38
Dividend yield
Dividend yield
Average volume
373.90K
Average volume373.90K
High today
$4.15
High today$4.15
Low today
$3.19
Low today$3.19
Open price
$4.00
Open price$4.00
Volume
2.32M
Volume2.32M
52 Week high
$4.83
52 Week high$4.83
52 Week low
$2.80
52 Week low$2.80

Stock Snapshot

The current X4 Pharmaceuticals(XFOR) stock price is $3.50, with a market capitalization of 347.51M. The stock trades at a price-to-earnings (P/E) ratio of -3.38.

As of 2026-09-08, X4 Pharmaceuticals(XFOR) stock has fluctuated between $3.19 and $4.15. The current price stands at $3.50, placing the stock +9.7% above today's low and -15.7% off the high.

X4 Pharmaceuticals(XFOR) shares are trading with a volume of 2.32M, against a daily average of 373.9K.

During the past year, X4 Pharmaceuticals(XFOR) stock moved between $2.80 at its lowest and $4.83 at its peak.

During the past year, X4 Pharmaceuticals(XFOR) stock moved between $2.80 at its lowest and $4.83 at its peak.

XFOR News

TipRanks 11h
X4 Pharmaceuticals gains FDA support for 4WARD trial

X4 Pharmaceuticals ( (XFOR) ) has issued an update. X4 Pharmaceuticals, a Boston-based biopharmaceutical company specializing in therapies for rare hematology...

TipRanks 11h
X4 Pharmaceuticals announces results from Type C Meeting with FDA

X4 Pharmaceuticals (XFOR) announced the outcome of its Type C Meeting with the FDA related to the global 4WARD Phase 3 clinical trial. The purpose of the meetin...

Nasdaq 11h
X4 Pharma Reports Positive Outcome Of Type C Meeting With FDA Related To 4WARD Phase 3 Trial

(RTTNews) - X4 Pharmaceuticals (XFOR) announced positive outcome of Type C Meeting with the FDA related to the global 4WARD Phase 3 clinical trial. The purpose...

X4 Pharma Reports Positive Outcome Of Type C Meeting With FDA Related To 4WARD Phase 3 Trial

People also own

Based on the portfolios of people who own XFOR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.